SPARC

Cerus Corporation Announces Positive Topline Results for the Phase 3 Clinical Trial of the INTERCEPT Blood System for Red Blood Cells in Cardiovascular Surgery Patients

Retrieved on: 
Tuesday, March 19, 2024
Medical Supplies, Biotechnology, Practice Management, Other Health, Health, General Health, Health Technology, Medical Devices, Hospitals, Surgery, Clinical Trials, Red blood cell, STARS, Platelet, SPARC, Incidence, AKI, Patient, Corporation, Mitt, News, CERS, RBC, Acute kidney injury, Clinical trial, Antibody, Transfusion medicine, PMA, Safety, DSMB, Data, Food, FDA, Physician, Cerus Corporation, Pharmaceutical industry

Cerus Corporation (Nasdaq: CERS) today announced positive topline results for ReCePI, a pivotal Phase 3 clinical trial of pathogen reduced INTERCEPT Red Blood Cells (INTERCEPT RBCs) transfused to complex cardiac surgery patients.

Key Points: 
  • Cerus Corporation (Nasdaq: CERS) today announced positive topline results for ReCePI, a pivotal Phase 3 clinical trial of pathogen reduced INTERCEPT Red Blood Cells (INTERCEPT RBCs) transfused to complex cardiac surgery patients.
  • There was no clinical significance related to treatment-emergent RBC antibodies observed in five patients receiving INTERCEPT RBCs.
  • This safety endpoint is also being explored in the Company’s ongoing RedeS Phase 3 clinical trial of INTERCEPT RBCs.
  • “We are extremely pleased by the positive topline results of the ReCePI clinical trial,” stated Richard Benjamin, M.D., Ph.D., Cerus’ chief medical officer and principal investigator for the ReCePI clinical trial.

Biswas Family Foundation, Milken Institute Announce $15 Million in Funding for Research at the Intersection of AI and Health

Retrieved on: 
Tuesday, March 12, 2024
Technology, General Health, Infectious Diseases, Foundation, Philanthropy, Science, Biotechnology, Health, Health Technology, Other Philanthropy, Other Science, Research, Other Technology, Other Health, Pharmaceutical, Artificial Intelligence, Oncology, Gladstone Institutes, Diagnosis, Health informatics, Harvard Medical School, Computational biology, SPARC, Transformative use, Test management, Computer science, Data science, Disease, Assistant, Massachusetts Institute of Technology, Associate, Chatbot, Partnership, Genetics, Patient, Common, Artificial intelligence, AI, Doctor of Philosophy, Interpretation, Investment, Stanford University, Milken Institute, Genetic distance, Medical device

The Biswas Family Foundation , in partnership with the Milken Institute Science Philanthropy Accelerator for Research and Collaboration (SPARC) , is pleased to announce the inaugural recipients of the Transformative Computational Biology Grant Program .

Key Points: 
  • The Biswas Family Foundation , in partnership with the Milken Institute Science Philanthropy Accelerator for Research and Collaboration (SPARC) , is pleased to announce the inaugural recipients of the Transformative Computational Biology Grant Program .
  • Five multidisciplinary research teams will receive nearly $14 million total in grant funding for projects aiming to drive translational impact and the advancement of artificial intelligence (AI) models in clinical settings for diagnosis and treatment.
  • Additional support to enhance AI and computational biology research, inclusive of a gift to the Arc Institute , marks a total of $15 million in giving for the Biswas Family Foundation for this interdisciplinary field, and the beginning of more support.
  • To learn more about the Transformative Computational Biology Grant Program and to read the Giving Smarter Guide, visit: https://bit.ly/3Vae8Kq .

Research Team Progresses to Final Phase in NIH Competition, Pioneering Autonomic Neuromodulation to Expand Applications for Spinal Stimulation

Retrieved on: 
Thursday, March 21, 2024
Kessler Institute for Rehabilitation, Research, Blood pressure, Reward, Health, TIM, Applied Physics Laboratory, Reynolds Center, Johns Hopkins, SPARC, Learning, Caregiver, News, Rehabilitation, University, Doctor of Philosophy, MD, Quality of life, NIH, Peripheral, Kessler Foundation, Competition, Tetraplegia, Autonomic nervous system, Mobility, Safety, University of Louisville, Neurostimulation, Self-management, Dysautonomia, Bangladesh Technical Education Board, Select Medical, Common Fund for Commodities, Pharmaceutical industry

EAST HANOVER, N.J., March 21, 2024 /PRNewswire/ -- Marking significant progress towards improving the lives of individuals with spinal cord injuries, Kessler Foundation, University of Louisville, and John Hopkins Applied Physics Laboratory (with the support of Medtronic) have collaboratively won the $1,000,000 prize for Phase 2 of the Neuromod Prize for their project titled, "Neuromodulation of the lumbosacral spinal cord for improvement of autonomic function after spinal cord injury." With this win, the team advances to compete for the Phase 3 prize pool of $5 million.

Key Points: 
  • With this win, the team advances to compete for the Phase 3 prize pool of $5 million.
  • Phase 1 called for innovative therapy concepts and development plans, leading to Phase 2's proof-of-concept studies by the eight selected teams.
  • On February 27, 2024, the NIH announced the four Phase 2 victors, marking a breakthrough moment in neuromodulation research.
  • "Most importantly, what we are learning and sharing about neuromodulation through this Competition will influence new approaches to treating other types of disabling autonomic dysfunction."

Cognition Therapeutics Presents Analyses at AD/PD™ 2024 Correlating Proteomic Findings with Treatment Effect of CT1812 in Alzheimer’s Disease Studies

Retrieved on: 
Wednesday, March 6, 2024
Alzheimer's disease, Research, Neuron, Cognition, Neuroinflammation, SPARC, Conference, Biomarker, Therapy, EEG, Protein, CSF, SHINE, Publication, Autophagy, Pharmaceutical industry

The three posters, which are listed below, summarize proteomic analyses from the completed SEQUEL and SPARC studies, which were conducted in adults with mild-to-moderate Alzheimer’s disease.

Key Points: 
  • The three posters, which are listed below, summarize proteomic analyses from the completed SEQUEL and SPARC studies, which were conducted in adults with mild-to-moderate Alzheimer’s disease.
  • These posters identify candidate protein biomarkers that correlate with improvements observed in SEQUEL participants treated with CT1812, Cognition’s lead candidate.
  • Pathways identified in these proteomic analyses support a role for CT1812 in modulating Aβ biology and neuroinflammation, among other disease-relevant processes.
  • “Analyses of CSF samples from these studies build on our efforts to identify candidate biomarkers of CT1812 treatment effect,” explained Mary Hamby, Ph.D. , VP of research at Cognition Therapeutics.

Canon Solutions America Recognized by William Paterson University for Contributions to Russ Berrie Institute for Professional Sales

Retrieved on: 
Tuesday, February 20, 2024
Student, William Paterson University, SPARC, Growth, Plaque, University, Robotics, Kid Brands, Environment, Nursing

Education—and the enhancement of the next generation of business leaders—is a strong focus point for Canon Solutions America.

Key Points: 
  • Education—and the enhancement of the next generation of business leaders—is a strong focus point for Canon Solutions America.
  • To that end, the company has provided support for both William Paterson’s Russ Berrie Institute for Professional Sales and the annual competition, with high-ranking and experienced sales employees offering valuable instruction to students interested in the sales profession.
  • Additionally, Canon Solutions America personnel have also served as judges for the contest, including Michael Mellusi, vice president, Sales, Workplace Technologies and Services.
  • Two current Canon Solutions America sales representatives in Roseland, New Jersey are William Paterson graduates and alumni of the Russ Berrie Institute for Professional Sales.

New Initiative Launched to Accelerate the Use of AI in the Fight Against Neurodegenerative Diseases

Retrieved on: 
Tuesday, February 13, 2024
Master of Science, Artificial intelligence, AI, Gates Ventures, Rain, Richard Rainwater, Partnership, Health, SPARC, MBA, Neurodegenerative disease, Business development, King's College London, Prevalence, Patient, Milken Institute, Harvard Business School, Research, Parkinson's disease, Brain, Medical device

OAKLAND, Calif., Feb. 13, 2024 /PRNewswire/ -- The 10,000 Brains Project, an independent 501(c)(3) nonprofit organization, has been launched to promote the ethical use of artificial intelligence (AI) in the fight against Alzheimer's, Parkinson's, and other neurodegenerative diseases. The organization's mission is to provide the leadership, expertise, and financial support needed to ensure that researchers can rapidly adopt this powerful new technology in the search for better diagnostics and treatments for patients in need.

Key Points: 
  • Neurodegeneration is perhaps the most complex challenge in healthcare and the development of treatments has proven resistant to traditional research methods.
  • Patrick Brannelly, a seasoned executive in nonprofit and entrepreneurial ventures, has been named the founding CEO of The 10,000 Brains Project.
  • We are excited to build a research roadmap that will show how private funding can accelerate this important area of medical research."
  • First, solving neurodegenerative diseases will require researchers to recognize the full diversity of human brains; every person's brain is different, and their disorders can take a variety of different paths.

Sigma Defense Hosts Inaugural Python Day for Special Operations Forces Children at SPARC - East Facility

Retrieved on: 
Tuesday, January 16, 2024
Woman, Python, Special forces, SPARC, History, Innovation, Special operations, Beret, Parent, USSOCOM, Intelligence, Education, SWA, Arms industry

The event took place at the Sigma Defense Prototyping and Advanced Research Center (SPARC) – East facility in Fayetteville, NC, welcoming 16 children of Special Operations Forces (SOF) service members to build and use Raspberry Pi devices to learn Python coding.

Key Points: 
  • The event took place at the Sigma Defense Prototyping and Advanced Research Center (SPARC) – East facility in Fayetteville, NC, welcoming 16 children of Special Operations Forces (SOF) service members to build and use Raspberry Pi devices to learn Python coding.
  • The initiative was sponsored by the Shadow Warrior Association (SWA), Task Force Dagger Special Operations Foundation, and the Special Forces Charitable Trust.
  • Task Force Dagger Special Operations Foundation's mission aids wounded, ill, or injured US Special Operations Command (USSOCOM) members and their families.
  • Sigma Defense is committed to initiatives that contribute to the well-being and education of the families associated with the Special Operations Forces.

Renowned Cosmetic Surgeon Victoria Johnson, M.D. Releases Memoir to Inspire Readers, Patients to Keep Moving Forward

Retrieved on: 
Tuesday, January 9, 2024
Titan, Dream, Family, Empowerment, Community college, Patient, Autobiography, Barnes & Noble, MD, Plastic, Life, Multimedia, SPARC, Oklahoma City Community College, Reader, Sale, Tongue, Parent, Education, Bookshop (company), Favourite, Book

OKLAHOMA CITY, Jan. 9, 2024 /PRNewswire/ -- Foreword Publicity is pleased to announce the release From Trophy Wife to Cosmetic Surgeon, written by Victoria Johnson, M.D.

Key Points: 
  • OKLAHOMA CITY, Jan. 9, 2024 /PRNewswire/ -- Foreword Publicity is pleased to announce the release From Trophy Wife to Cosmetic Surgeon, written by Victoria Johnson, M.D.
  • In her 20 years in practice, people frequently ask, how did Dr. Victoria Johnson become so well known?
  • As a cosmetic surgeon, one of Johnson's greatest joys is helping patients see their true beauty, not just the exterior.
  • From Trophy Wife to Cosmetic Surgeon (978-1-957262-80-2) is available on Amazon, Barnes & Noble, Bookshop.org, and wherever books are sold.

Cognition Therapeutics CEO Issues Letter to Shareholders

Retrieved on: 
Thursday, January 4, 2024
Biology, Work, Geographic atrophy, SHIMMER, Alzheimer's disease, Dementia, Neuron, ACTC, Iris (anatomy), EEG, Lewy body, RPE, Antibody, Letter, AMD, Brain, Therapy, Clinical trial, ADAS, SPARC, Society, DLB, SHINE, Cognition, Vance DeGeneres, Biomarker, Toxicity, Optimism, Manuscript, Cell, Patient, Magnification, Synapse, Diagnosis, Safety, Pharmaceutical industry

PURCHASE, N.Y., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage neuroscience company developing drugs that treat neurodegenerative disorders by regulating cellular damage response pathways (the “Company” or “Cognition”), today announced that CEO Lisa Ricciardi has issued a Letter to Shareholders to provide an update on recent pipeline developments and a preview of the company’s strategy in 2024. The full text of the letter follows:

Key Points: 
  • PURCHASE, N.Y., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage neuroscience company developing drugs that treat neurodegenerative disorders by regulating cellular damage response pathways (the “Company” or “Cognition”), today announced that CEO Lisa Ricciardi has issued a Letter to Shareholders to provide an update on recent pipeline developments and a preview of the company’s strategy in 2024.
  • The full text of the letter follows:
    The year ahead holds great promise for Cognition Therapeutics.
  • As we work towards these important milestones, we take stock of the achievements that give rise to optimism at Cognition Therapeutics and in the broader medical community.
  • For Cognition, expanding the pipeline for CT1812 to dry AMD has the potential to grow Cognition’s value across multiple age-related diseases.

KBR Teams with HJF, Awarded Critical Contract to Aid Military Neuroscience Research

Retrieved on: 
Monday, December 18, 2023
Research, NYSE, Military medicine, Force, Health, UCSF, NASA, HJF, Chronic traumatic encephalopathy, Therapy, Medical research, University, HHPC, Brain damage, Growth, Knowledge, Military personnel, CTE, Military, SPARC, Energy Savings Performance Contract, Education, KBR, Nursing, Family

HOUSTON, Dec. 18, 2023 /PRNewswire/ -- KBR (NYSE: KBR) is pleased to join forces with The Henry M. Jackson Foundation for the Advancement of Military Medicine (HJF) on an important contract to support neuroscience research for service members.

Key Points: 
  • HOUSTON, Dec. 18, 2023 /PRNewswire/ -- KBR (NYSE: KBR) is pleased to join forces with The Henry M. Jackson Foundation for the Advancement of Military Medicine (HJF) on an important contract to support neuroscience research for service members.
  • Research will be done in collaboration with the Uniformed Services University (the nation's only federal health sciences university), and the University of California San Francisco (UCSF).
  • Under the terms of the Service Personnel Advancing Research in Chronic Traumatic Encephalopathy (SPARC) contract, KBR will provide outreach, education and data analytics to support critical neuroscience research for the prevention and treatment of military members with chronic traumatic encephalopathy (CTE).
  • KBR also continues to collaborate with the Airmen Readiness and Medical Research (ARMR) contract on various brain scanning and neuroimaging projects.